Mylan N.V. (MYL) vs. Sophiris Bio (SPHS) Critical Contrast

Sophiris Bio (NASDAQ: SPHS) and Mylan N.V. (NASDAQ:MYL) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitabiliy, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

Profitability

This table compares Sophiris Bio and Mylan N.V.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sophiris Bio N/A -121.18% -52.14%
Mylan N.V. 4.59% 23.69% 7.92%

Risk and Volatility

Sophiris Bio has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500. Comparatively, Mylan N.V. has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Sophiris Bio and Mylan N.V., as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sophiris Bio 0 0 5 0 3.00
Mylan N.V. 0 8 11 2 2.71

Sophiris Bio currently has a consensus target price of $6.60, indicating a potential upside of 233.32%. Mylan N.V. has a consensus target price of $50.05, indicating a potential upside of 57.45%. Given Sophiris Bio’s stronger consensus rating and higher probable upside, equities analysts plainly believe Sophiris Bio is more favorable than Mylan N.V..

Valuation & Earnings

This table compares Sophiris Bio and Mylan N.V.’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Sophiris Bio N/A N/A -$10.78 million ($0.49) -4.04
Mylan N.V. $11.61 billion 1.47 $3.80 billion $1.00 31.79

Mylan N.V. has higher revenue and earnings than Sophiris Bio. Sophiris Bio is trading at a lower price-to-earnings ratio than Mylan N.V., indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

5.5% of Sophiris Bio shares are held by institutional investors. Comparatively, 70.2% of Mylan N.V. shares are held by institutional investors. 3.9% of Sophiris Bio shares are held by insiders. Comparatively, 0.7% of Mylan N.V. shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Mylan N.V. beats Sophiris Bio on 9 of the 13 factors compared between the two stocks.

Sophiris Bio Company Profile

Sophiris Bio, Inc., formerly Protox Therapeutics Inc., is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate). The Company has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan. Sophiris Bio, Inc. is advancing a pipeline of receptor targeted fusion proteins based on three complementary technology platforms: PORxin, INxin and HUMxin. It focuses on diseases of the prostate via its PORxin platform candidate, PRX302, which has completed three clinical trials for the treatment of BPH, as well as two clinical trials for the treatment of localized recurrent prostate cancer.

Mylan N.V. Company Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector. Its Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients. The Company also markets ULTIVA, which is an analgesic agent.

Receive News & Ratings for Sophiris Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Los Angeles Dodgers Move 50 Games Over .500
Los Angeles Dodgers Move 50 Games Over .500
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury
Chicago Cubs Must Survive Without Willson Contreras
Chicago Cubs Must Survive Without Willson Contreras
Cleveland Indians Acquire Jay Bruce From New York Mets
Cleveland Indians Acquire Jay Bruce From New York Mets
Injury to CC Sabathia Adds to Yankees’ Concerns
Injury to CC Sabathia Adds to Yankees’ Concerns


Leave a Reply

 
© 2006-2017 BBNS.